- Home
- WWW vs ORKA Comparison
WWW vs ORKA Comparison
Compare WWW & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWW | ORKA |
|---|---|---|
| Founded | 1883 | 2004 |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | Shoe Manufacturing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WWW | ORKA |
|---|---|---|
| Price | $18.65 | $32.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $23.25 | ★ $49.73 |
| AVG Volume (30 Days) | ★ 1.6M | 478.2K |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $1,851,500,000.00 | N/A |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $4.83 | N/A |
| P/E Ratio | $16.94 | ★ N/A |
| Revenue Growth | ★ 3.61 | N/A |
| 52 Week Low | $9.58 | $5.49 |
| 52 Week High | $32.80 | $36.51 |
Technical Indicators
Market Signals| Indicator | WWW | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 50.81 |
| Support Level | $17.68 | $31.15 |
| Resistance Level | $18.49 | $35.46 |
| Average True Range (ATR) | 0.75 | 1.98 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 54.31 | 28.05 |
Price Performance
Historical ComparisonAbout WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.